Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo

CPX-351 is a liposomally encapsulated 5:1 molar ratio of cytarabine and daunorubicin that recently received regulatory approval for the treatment of therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes based on improved overall survival compared to standard cytarab...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincelette, Nicole D., Ding, Husheng, Huehls, Amelia M., Flatten, Karen S., Kelly, Rebecca L., Kohorst, Mira A., Webster, Jonathan, Hess, Allan D., Pratz, Keith W., Karnitz, Larry M., Kaufmann, Scott H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400938/
https://www.ncbi.nlm.nih.gov/pubmed/30837643
http://dx.doi.org/10.1038/s41598-019-40218-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400938/
https://www.ncbi.nlm.nih.gov/pubmed/30837643
http://dx.doi.org/10.1038/s41598-019-40218-0

Ejemplares similares